Alto Neuroscience Inc. (ANRO) Stock
NYSE · ANRO
26.80
Fundamentals
Market cap
$1.04B
Price / Earnings ratio
-12.7x
Price / Sales ratio
N/A
Price / Book ratio
4.9x
Return on assets
-39.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
NeutralANROSeptember 9, 2026
Business WireNeutral
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Business Wire
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
NeutralANROAugust 27, 2026
Business WireNeutral
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO

Business Wire
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NeutralANROAugust 12, 2026
Business WireNeutral
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ANRO

Business Wire
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
NeutralANROJuly 13, 2026
Business WireNeutral
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
ANRO
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy2
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 9 articles
published over the past 14 days
Latest news

Business Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
NeutralANROSeptember 9, 2026
Business WireNeutral
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Business Wire
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
NeutralANROAugust 27, 2026
Business WireNeutral
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO

Business Wire
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NeutralANROAugust 12, 2026
Business WireNeutral
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ANRO

Business Wire
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
NeutralANROJuly 13, 2026
Business WireNeutral
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
ANRO

Business Wire
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
NeutralANROJune 15, 2026
Business WireNeutral
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
ANRO

Stocktwits
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
NeutralANROApril 2, 2026
StocktwitsNeutral
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
ANRO

Stocktwits
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
NeutralANROApril 1, 2026
StocktwitsNeutral
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
ANRO

Zacks Investment Research
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
NeutralANRONovember 10, 2025
Zacks Investment ResearchNeutral
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
ANRO

24/7 Wall Street
5 Stocks Under $10 Growing 50% Or More
NeutralANROAugust 11, 2024
24/7 Wall StreetNeutral
5 Stocks Under $10 Growing 50% Or More
ANRO
About Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
SectorHealthcare
IndustryBiotechnology
Employees68
CEODr. Amit Etkin M.D., Ph.D.
IPO DateFeb 2, 2024
HeadquartersMountain View, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, CEO & Chairman of the Board | 1977 |
| Mr. Nicholas C. Smith | CFO & President | 1989 |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer | 1974 |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor | 1962 |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary | 1975 |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer | 1966 |
| Ms. Jessica Powell | Chief Development Officer | 1975 |
Fundamentals
Valuation
Market cap$1.04B
Price-to-sales ratioN/A
Price-to-book value4.86
Price-earnings ratio-12.70
Return on Equity-47.00%
Return on SalesN/A
Return on Assets-39.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.42
Income Statement
Average volume546,111
EBITDA$-70.43M
1 year high (52w)$37.48
1 year low (52w)$3.77
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
67% Buy
33% Hold
0% Sell
Target price
$39.33
Est return
48.32%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.0 | +8.5 | +29.7 | -24.7 |



